Clinical trial NCT04675450: NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of n-Butylphthalide (NBP) Softgel Capsules Administered to Patients With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Breast Cancer
Peripheral Neuropathy
Lead sponsor: Conjupro Biotherapeutics, Inc.
Sponsor class: INDUSTRY
Collaborators: name: CSPC-NBP Pharmaceutical Co., Ltd.
First posted: 2020-12-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.

Detailed description: This is a multiple center, randomized, double-blind, Phase 2 study of NBP administered to women with metastatic breast cancer who receive nab-paclitaxel as therapy. Nab-paclitaxel will be administered at a dose \>260 mg/m2 every 3 weeks for 4 planned cycles. Subjects will begin receiving NBP orally at a dose of 400 mg administered every 12-hours (BID) or matching placebo 5 days (10 doses) prior to starting nab-paclitaxel therapy and continue to self-administer it BID until Visit 6/Day 100/Week 15. The primary objective is to evaluate the efficacy of NBP relative to placebo at preventing or reducing symptoms associated with nab-paclitaxel induced toxic neuropathy (CIPN). The secondary objectives include an evaluation the efficacy of NBP relative to placebo at preventing or attenuating taxane induced acute pain syndrome (TAPS), the evaluation of the safety and tolerability of NBP relative to placebo and to determine if NBP administration impacts the pharmacokinetics of nab-paclitaxel or if nab-paclitaxel affects the pharmacokinetics of NBP.

Eligibility criteria: Inclusion Criteria

Subjects are eligible to participate in the study only if all the following criteria apply:

1. Women aged ≥18 and ≤75 years.
2. Pathologically confirmed metastatic breast cancer.
3. Are candidates for initial therapy with nab-paclitaxel, at a dose of \>260 mg/m2 every 3 weeks for 4 planned cycles.
4. Concomitant antitumor drugs used to treat the underlying malignancy, including immunotherapies, other than nab-paclitaxel will be allowed.
5. Eastern Cooperative Oncology Group (ECOG) performance status scores of 0 - 2.
6. Life expectancy ≥6 months.
7. Women of childbearing potential (WOCBP) must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening and be practicing a medically acceptable method of contraception with an annual failure rate of less than 1% until the completion of the trial or 30 days after discontinuation of study treatment. Women are considered not childbearing if they are \>1 year postmenopausal or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation).
8. Able to complete study questionnaires by themselves or with assistance.
9. Capable of understanding the purpose and risks of the study and able to provide informed consent by signing the informed consent form.
10. Able to swallow softgel capsules as determined by the investigator.
11. Able to comply with all study requirements. Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

1. Non-metastatic breast cancer.
2. Subjects who are pregnant, lactating/breast-feeding, or plan to become pregnant within the next 3 months.
3. History of poorly controlled diabetes mellitus (hemoglobin A1C \>8.0 at the time of the Screening visit).
4. History of fibromyalgia.
5. History of any signs or symptoms suggestive of neuropathy within 30 days of Screening as determined by the investigator based on the neurological examination.
6. History of taking any neurotoxic drugs within 6 months of Screening.
7. Current use of drugs that are used to treat neuropathic pain (eg, gabapentin, pregabalin, and duloxetine) within 30 days of Screening.
8. Current diagnosis of malignancy other than breast cancer.
9. Absolute neutrophil count \<1.5 x 109 cells/L.
10. Platelet count \<100,000 x 109/L.
11. Hemoglobin level \<9 g/dL at Screening without transfusion (transfusion independent).
12. Corrected QTcF \>470 msec (single tracing) at Screening and prior to randomization.
13. Chronic renal or hepatic disease.
14. Clinically significant renal dysfunction including serum creatinine level \>1.5 mg/dL or calculated creatinine clearance ≥50 mL/minute at Screening.
15. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \>2.0 x upper limits of normal (ULN), or a bilirubin \>1.5 x ULN unless in the setting of known Gilbert's disease at Screening.
16. History of HIV, hepatitis B, hepatitis C, or tuberculosis.
17. Major surgical procedures ≤30 days prior to starting study drug, or minor surgical procedures ≤7 days prior to starting study drug.
18. History of alcohol or drug dependence or is known to have abused alcohol within 30 days prior to screening.
19. Unwilling to abstain from alcohol and recreational drugs (with exception for medical marijuana) throughout the duration of participation in the study.
20. Positive urine drug screen at Screening (with exception for medical marijuana which is allowed).
21. Known hypersensitivity to celery or soybeans.
22. Known serious hypersensitivity to paclitaxel
23. Received treatment with any other investigational drug within 30 days before screening, was previously treated with NBP, is currently taking celery seed extract, or is currently participating in another clinical study
24. Any other reasons that in the opinion of the investigator make the subject unsuitable for enrollment.

Primary outcomes:
measure: Mean Change from Baseline in EORTC Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Sensory Subscale
timeFrame: Baseline and weeks 5, 8, 11 and 15
Secondary outcomes:
measure: Number of Participants Requiring Rescue Medication
timeFrame: 15 weeks
measure: Days Free of Rescue Medication
timeFrame: 15 weeks
measure: Mean Change from Baseline in the Brief Pain Inventory Short Form (mBPI-SF) score.
timeFrame: 15 weeks
measure: Number of Participants with Treatment-Emergent Adverse Events
timeFrame: 19 weeks
measure: Area Under the Curve (AUC) for NBP
timeFrame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7
measure: Cmax for NBP
timeFrame: Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7
measure: Tmax for NBP
timeFrame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7
measure: Area Under the Curve for Paclitaxel
timeFrame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7
measure: Cmax for Paclitaxel
timeFrame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7
measure: Tmax for Paclitaxel
timeFrame: Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7
Other outcomes:
Locations:
Study officials:
affiliation: Conjupro Biotherapeutics, Inc.
name: Qingxi Wang, PhD
role: STUDY_DIRECTOR
References: